<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Amiloride</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00594</strong>&#160; (APRD00790, EXPT00514)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman&#8217;s The Pharmacological Basis of Therapeutics, 9th ed, p705)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00594/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00594/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00594.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00594.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00594.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00594.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00594.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00594">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Amilorid</td><td>German</td><td>INN</td></tr><tr><td>Amilorida</td><td>Spanish</td><td>INN</td></tr><tr><td>Amiloridum</td><td>Latin</td><td>INN</td></tr><tr><td>Amipramidin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Amipramidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Amyloride</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Amiloride Hydrochloride</strong>
          <div class="cas">17440-83-4</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000270/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000270/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: LTKVFMLMEYCWMK-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 301.045692731</li>
              <li>Average Mass: 302.119</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000270">DBSALT000270</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Arumil</td><td>Sharp &amp; Dohme</td></tr><tr><td>Diurex</td><td>Orion</td></tr><tr><td>Kaluril</td><td>Alphapharm</td></tr><tr><td>Midamor</td><td>Merck</td></tr><tr><td>Modamide</td><td>Merck</td></tr><tr><td>Moduret</td><td>Bristol-Myers Squibb</td></tr><tr><td>Moduretic</td><td>Merck</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Alti-Amiloride HCTZ</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Ami-Hydro Tab</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Apo-Amilzide Tab</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Gen-Amilazide</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Miloride</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Moduret</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Novamilor Tab USP</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Nu-Amilzide 5/50 mg Tab</td><td>Amiloride and Hydrochlorothiazide</td></tr><tr><td>Riva-Amilzide 5/50 mg</td><td>Amiloride and Hydrochlorothiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/diuretics">Diuretics</a></li>
<li><a href="/mesh/epithelial-sodium-channel-blockers">Epithelial Sodium Channel Blockers</a></li>
<li><a href="/mesh/acid-sensing-ion-channel-blockers">Acid Sensing Ion Channel Blockers</a></li>
<li><a href="/mesh/sodium-channel-blockers">Sodium Channel Blockers</a></li></ul></td></tr><tr><th>CAS number</th><td>2016-88-8</td></tr><tr><th>Weight</th><td>Average: 229.627<br>Monoisotopic: 229.04788562</td></tr><tr><th>Chemical Formula</th><td>C<sub>6</sub>H<sub>8</sub>ClN<sub>7</sub>O</td></tr><tr><th>InChI Key</th><td>XSDQTOBWRPYKKA-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrazines</td></tr><tr><th>Direct parent</th><td>Pyrazinecarboxamides</td></tr><tr><th>Alternative parents</th><td>Primary Aromatic Amines; Aryl Chlorides; Guanidines; Amidines; Enolates; Polyamines; Carboxylic Acid Amides; Organochlorides</td></tr><tr><th>Substituents</th><td>aryl chloride; aryl halide; primary aromatic amine; guanidine; carboxamide group; amidine; enolate; carboxylic acid derivative; polyamine; organohalogen; organochloride; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrazinecarboxamides. These are compounds containing a pyrazine ring which bears a carboxamide.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.</td></tr><tr><th>Pharmacodynamics</th><td>Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. The risk is high in concurrent use of ACE inhibitors or spironolactone. Patients are also advised not to use potassium-containing salt replacements.</td></tr><tr><th>Mechanism of action</th><td>Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. This promotes the loss of sodium and water from the body, but without depleting potassium. Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. Amiloride is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.</td></tr><tr><th>Absorption</th><td>Readily absorbed following oral administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys.</p></td></tr><tr><th>Route of elimination</th><td>Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys.  About 50 percent of a 20 mg dose of amiloride HCl is excreted in the urine and 40 percent in the stool within 72 hours.</td></tr><tr><th>Half life</th><td>Plasma half-life varies from 6 to 9 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>No data are available in regard to overdosage in humans. The oral LD<sub>50</sub> of amiloride hydrochloride (calculated as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the strain. The most likely signs and symptoms to be expected with overdosage are dehydration and electrolyte imbalance.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Amiloride Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9408</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7193</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7207</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9282</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9677</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8122</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8253</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8778</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6687</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9577</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9295</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9733</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9605</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9107
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9119
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5469 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9838
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8945
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Par pharmaceutical inc</li>
<li>Sigmapharm laboratories llc</li>
<li>Paddock laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Kaiser Foundation Hospital</li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.risingpharma.com">Rising Pharmaceuticals</a></li>
<li><a href="http://sigmapharm.com">Sigmapharm Laboratories LLC</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00542">Benazepril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00796">Candesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01197">Captopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01340">Cilazapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>Decreases the antiarrhythmic effect of quinidine</td></tr><tr><td><a href="/drugs/DB00584">Enalapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels during concomitant threapy.</td></tr><tr><td><a href="/drugs/DB00876">Eprosartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01342">Forasartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00492">Fosinopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01029">Irbesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00722">Lisinopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00691">Moexipril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00790">Perindopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01344">Polystyrene sulfonate</a></td><td>Risk of alkalosis in renal impairment</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00881">Quinapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Amiloride may decrease the therapeutic effect of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if amiloride if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Decreases the antiarrhythmic effect of quinidine</td></tr><tr><td><a href="/drugs/DB00178">Ramipril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01347">Saprisartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01348">Spirapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01349">Tasosartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Telmisartan may increase the hyperkalemic effect of Amiloride. Monitor for increased serum potassium concentrations during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00177">Valsartan</a></td><td>Increased risk of hyperkalemia</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid drastic changes in dietary habit.</li>
<li>Avoid natural licorice.</li>
<li>Avoid salt substitutes containing potassium.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>